Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enzyme replacement therapy in type III Gaucher disease.
Tylki-Szymańska A, Czartoryska B. Tylki-Szymańska A, et al. J Inherit Metab Dis. 1999 Apr;22(2):203-4. doi: 10.1023/a:1005495229655. J Inherit Metab Dis. 1999. PMID: 10234625 No abstract available.
Management of neuronopathic Gaucher disease: a European consensus.
Vellodi A, Bembi B, de Villemeur TB, Collin-Histed T, Erikson A, Mengel E, Rolfs A, Tylki-Szymanska A; Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease. Vellodi A, et al. J Inherit Metab Dis. 2001 Jun;24(3):319-27. doi: 10.1023/a:1010514614570. J Inherit Metab Dis. 2001. PMID: 11486896 Review. No abstract available.
Therapeutic goals in the treatment of Gaucher disease.
Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymańska A. Pastores GM, et al. Semin Hematol. 2004 Oct;41(4 Suppl 5):4-14. doi: 10.1053/j.seminhematol.2004.07.009. Semin Hematol. 2004. PMID: 15468045 Review.
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.
Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, Erikson A, Giraldo P, Goldblatt J, Hollak C, Ida H, Kaplan P, Kolodny EH, Mistry P, Pastores GM, Pires R, Prakash-Cheng A, Rosenbloom BE, Scott CR, Sobreira E, Tylki-Szymańska A, Vellodi A, vom Dahl S, Wappner RS, Zimran A; International Collaborative Gaucher Group (ICGG). Weinreb NJ, et al. Semin Hematol. 2004 Oct;41(4 Suppl 5):15-22. doi: 10.1053/j.seminhematol.2004.07.010. Semin Hematol. 2004. PMID: 15468046
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.
Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N. Cox TM, et al. J Inherit Metab Dis. 2008 Jun;31(3):319-36. doi: 10.1007/s10545-008-0779-z. Epub 2008 May 23. J Inherit Metab Dis. 2008. PMID: 18509745 Review.
Management of neuronopathic Gaucher disease: revised recommendations.
Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, Mengel E, Erikson A, Schiffmann R. Vellodi A, et al. J Inherit Metab Dis. 2009 Oct;32(5):660-664. doi: 10.1007/s10545-009-1164-2. Epub 2009 Aug 5. J Inherit Metab Dis. 2009. PMID: 19655269
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM. Hollak CE, et al. Blood Cells Mol Dis. 2010 Jan 15;44(1):41-7. doi: 10.1016/j.bcmd.2009.09.006. Epub 2009 Oct 4. Blood Cells Mol Dis. 2010. PMID: 19804996
275 results